Abstract: Antenatal multiple micronutrient supplementation (MMS) is an intervention that can help reach three of the six global nutrition targets, either directly or indirectly: a reduction in low birth weight, stunting, and anaemia in women of reproductive age. To support global guideline development and national decision\u2010making on investments into maternal nutrition, Nutrition International developed a modelling tool called the MMS cost\u2013benefit tool to help users understand whether antenatal MMS is better value for money than iron and folic acid supplementation (IFAS) during pregnancy. The MMS cost\u2013benefit tool can generate estimates on the potential health impact, budget impact, economic value, cost\u2010effectiveness and benefit\u2013cost ratio of investing in MMS compared to IFAS in LMICs. In the 33 countries with data included in the tool, the MMS cost\u2013benefit tool shows that transitioning is expected to generate substantial health benefits in terms of morbidity and mortality averted and can be very cost\u2010effective in multiple scenarios for these countries. The cost per DALY averted averages at US$ 23.61 and benefit\u2013cost ratio ranges from US$ 41\u2013US$ 1304: $1.0, which suggest MMS is good value for money compared with IFAS. With its user\u2010friendly design, open access availability, and online data\u2010driven analytics, the MMS cost\u2013benefit tool can be a powerful resource for governments and nutrition partners seeking timely and evidence\u2010based analyses to inform policy\u2010decision and investments towards the scale\u2010up of MMS for pregnant women globally.<\/p>\n","protected":false},"excerpt":{"rendered":"